As previously announced, the company's board of directors resolved on a directed share issue of 10,000,000 shares at a subscription price of
As of today, the total number of registered and outstanding shares and votes of Vicore amounts to 81,847,979. Furthermore, the registered share capital amounts to
For further information, please contact:
This information is information that
About
Vicore is an innovative Swedish clinical-stage pharmaceutical company dedicated to creating life-changing treatments in diseases where the Angiotensin II type 2 receptor (AT2R) has a central protective role. The company currently has four development programs, VP01, VP02, VP03 and VP04. VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (IPF) and pulmonary artery hypertension (PAH). VP02 is a new formulation and delivery route of thalidomide and focuses on the underlying disease and the severe cough associated with IPF. In the VP03 program new AT2 receptor agonists are developed. VP04 is a clinically validated digital therapeutic in development for pulmonary fibrosis (PF) patients.
The company's shares (VICO) are listed on Nasdaq Stockholm's main market. For more information, see www.vicorepharma.com.
https://news.cision.com/vicore-pharma-holding-ab/r/increase-of-number-of-shares-and-votes-in-vicore-pharma,c3690999
https://mb.cision.com/Main/15668/3690999/1759528.pdf
(c) 2022 Cision. All rights reserved., source